We are live on ! Find out more
UNCY icon

Unicycive Therapeutics
UNCY

12 hedge funds and large institutions have $3.54M invested in Unicycive Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

727% more capital invested

Capital invested by funds: $428K → $3.54M (+$3.11M)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

33% more funds holding

Funds holding: 9 → 12 (+3)

0.59% more ownership

Funds ownership: 0.53% → 1.12% (+0.59%)

Holders
12
Holders Change
+3
Holders Change %
+33.33%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$715K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$92K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$69.5K
4
State Street
State Street
Massachusetts
+$34.9K
5
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$18.7K

Top Sellers

Rank Fund Capital Flow
1
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
California
-$34K
2
VF
Virtu Financial
New York
-$8K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.57K
4
Bank of America
Bank of America
North Carolina
-$5
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
1
Balyasny Asset Management
Illinois
$1.51M +$715K +71,735 New
NCM
2
Nantahala Capital Management
Connecticut
$1.36M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$242K +$92K +9,236 +407%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$201K +$69.5K +6,979 +267%
State Street
5
State Street
Massachusetts
$73.6K +$34.9K +3,504 New
CAPTRUST Financial Advisors
6
CAPTRUST Financial Advisors
North Carolina
$39.5K +$18.7K +1,880 New
TCM
7
Tandem Capital Management
New Jersey
$32.5K – – –
Two Sigma Advisers
8
Two Sigma Advisers
New York
$30.7K +$14.5K +1,460 New
OA
9
Oxbow Advisors
Texas
$24.9K +$11.8K +1,186 New
Squarepoint
10
Squarepoint
New York
$24.1K +$11.4K +1,146 New
TRCT
11
Tower Research Capital (TRC)
New York
$7K -$1.57K -158 -32%
Wells Fargo
12
Wells Fargo
California
$99 – – –
Osaic Holdings
13
Osaic Holdings
Arizona
$2 – – –
BOTOTLSJU
14
Board of Trustees of The Leland Stanford Junior University
California
– -$34K -6,302 Closed
VF
15
Virtu Financial
New York
– -$8K -1,546 Closed
Bank of America
16
Bank of America
North Carolina
– -$5 -1 Closed

UNCY Hedge Fund Activity: Q1 2023 in Review

12 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2023, worth a combined $3.54M — up 727% from $428K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new UNCY positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $715K. The largest seller was Board of Trustees of The Leland Stanford Junior University, exiting entirely with an estimated $34K sold.

  • 12 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2023, up from 9 in Q4 2022.
  • Funds reported $3.54M of Unicycive Therapeutics stock for Q1 2023, up 727% quarter-over-quarter.
  • 6 funds opened new Unicycive Therapeutics positions in Q1 2023 and 3 closed out, a net change of +3 holders.
  • The largest Unicycive Therapeutics buyer in Q1 2023 was Balyasny Asset Management, an estimated $715K added.
  • The largest Unicycive Therapeutics seller in Q1 2023 was Board of Trustees of The Leland Stanford Junior University, an estimated $34K sold.

Based on aggregated 13F filings for Q1 2023.